Oppenheimer analyst Leland Gershell reiterated a Buy rating on ADMA Biologics (NASDAQ: ADMA) yesterday and set a price target of $13. The company’s shares closed on Friday at $6.23, close to its 52-week high of $6.86.
Gershell observed:
“Last Thursday we hosted investor meetings with ADMA management in NYC. The discussions increased our confidence that ADMA will be able to achieve its regulatory goals with both RI-002 (BLA re-filing by YE). Moreover, we believe there is a chance that RI-002 could be approved ~one quarter earlier vs. expectations. We reiterate our Outperform rating and $13 PT as ADMA continues to execute on its near-term milestones.”
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -12.3% and a 14.3% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Avenue Therapeutics Inc, Evofem Biosciences Inc, and Urogen Pharma Ltd.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ADMA Biologics with a $10.70 average price target, which is a 71.7% upside from current levels. In a report issued on July 30, Chardan Capital also initiated coverage with a Buy rating on the stock with a $10 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.86 and a one-year low of $2.01. Currently, ADMA Biologics has an average volume of 313K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADMA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.
